Annovis Bio (ANVS) has filed a preliminary prospectus for an IPO of ~1.4M common shares at $6 – 8 per share. Underwriters’ over-allotment will be an additional ~214K shares.
Lead candidate is ANVS-401 for the potential treatment of Alzheimer’s and Parkinson’s diseases.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.